Peptide: difference between revisions
Diff·revision 18 → 19·12:12, 8 Feb 2025
Difference between revision 18 and revision 19 of Peptide. 6 lines changed; the page grew by 874 bytes.
| Revision 18 — 04:24, 21 Jan 2025 AmylinAmos (talk) add short description 4,059 bytes ±0 | Revision 19 — 12:12, 8 Feb 2025 SurmountSurma (talk) state that overlay gas is used and name it 4,933 bytes +874 | ||
|---|---|---|---|
| 35 | Non-proteinogenic residues are common in engineered peptides and are the main reason a peptide drug cannot generally be produced by biological expression. See [[Solid-phase peptide synthesis]]. | 35 | Non-proteinogenic residues are common in engineered peptides and are the main reason a peptide drug cannot generally be produced by biological expression. See [[Solid-phase peptide synthesis]]. |
| 36 | 36 | ||
| + | 37 | == Peptides as medicines == | |
| + | 38 | Peptides occupy a middle ground between small molecules and proteins. They bind large, flat protein-protein interfaces that small molecules bind poorly, while remaining accessible to chemical synthesis, which proteins are not.{{r|usp1503}} | |
| + | 39 | ||
| + | 40 | Their liabilities are equally characteristic. Oral bioavailability is negligible without a formulation strategy, because gastrointestinal proteases and the intestinal barrier remove them. Circulating half-life is short unless engineered — see [[Albumin binding half-life extension]]. They are chemically labile in solution in ways small molecules are not, which drives the reliance on [[Lyophilisation|lyophilised]] presentations and a [[Cold chain|cold chain]]. | |
| + | 41 | ||
| 37 | == References == | 42 | == References == |
| 38 | {{reflist}} | 43 | {{reflist}} |
| 39 | <ref name="iupac">International Union of Pure and Applied Chemistry and International Union of Biochemistry, ''Nomenclature and Symbolism for Amino Acids and Peptides'' (recommendations 1983; revised).</ref> | 44 | <ref name="iupac">International Union of Pure and Applied Chemistry and International Union of Biochemistry, ''Nomenclature and Symbolism for Amino Acids and Peptides'' (recommendations 1983; revised).</ref> |
| + | 45 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 40 | 46 | ||
| 41 | == See also == | 47 | == See also == |